Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
Bromazolam (1) ·
Clonazolam (1) ·
Deschloroetizolam (1) ·
Diclazepam (1) ·
Estazolam (1) ·
Eszopiclone (1) ·
Ethchlorvynol (1) ·
Flualprazolam (1) ·
Flubromazepam (1) ·
Flubromazolam (1) ·
Flunitrazepam (1) ·
Flunitrazolam (1) ·
Flurazepam (1) ·
Gaboxadol (1) ·
GHB (1) ·
Glutethimide (1) ·
Lactulose (1) ·
Lormetazepam (1) ·
Methaqualone (1) ·
Midazolam (1) ·
Nifoxipam (1) ·
Nitrazepam (1) ·
Pentobarbital (1) ·
Quazepam (1) ·
Ramelteon (1) ·
Secobarbital (1) ·
Tasimelteon (1) ·
Temazepam (1) ·
Triazolam (1) ·
Zaleplon (1) ·
Zopiclone (1)
None (9) ·
(none, never marketed) (1) ·
Dalmane (1) ·
Doral (1) ·
Doriden (1) ·
Halcion (1) ·
Hetlioz (1) ·
Imovane (1) ·
Kristalose, Constulose, Generlac, Enulose (1) ·
Lunesta (1) ·
Mogadon (1) ·
Nembutal (1) ·
Placidyl (1) ·
ProSom (1) ·
Quaalude (1) ·
Restoril (1) ·
Rohypnol (1) ·
Rozerem (1) ·
Seconal (1) ·
Sonata (1) ·
THIP (1) ·
Versed (1) ·
Xyrem (1)
None (3) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator (15) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
Melatonin receptor agonist (2) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1)
None (29) ·
Constipation: 15-30 mL PO daily (titrate to 1-2 soft stools/day); hepatic encephalopathy: 20-30 g (30-45 mL) PO/PR every 1-2 hours acutely until soft stools, then BID-QID to target 2-3 soft stools/day (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)
None (29) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 31 results in range #1 to #31.


